Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Stress signaling in pain control.

Avril T, Chevet E.

Science. 2019 Jul 19;365(6450):224-225. doi: 10.1126/science.aay2721. No abstract available.

PMID:
31320525
2.

CD90/Thy-1, a Cancer-Associated Cell Surface Signaling Molecule.

Sauzay C, Voutetakis K, Chatziioannou A, Chevet E, Avril T.

Front Cell Dev Biol. 2019 Apr 26;7:66. doi: 10.3389/fcell.2019.00066. eCollection 2019. Review.

3.

Emerging Roles of the Endoplasmic Reticulum Associated Unfolded Protein Response in Cancer Cell Migration and Invasion.

Limia CM, Sauzay C, Urra H, Hetz C, Chevet E, Avril T.

Cancers (Basel). 2019 May 6;11(5). pii: E631. doi: 10.3390/cancers11050631. Review.

4.

Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation.

Maurel M, Obacz J, Avril T, Ding YP, Papadodima O, Treton X, Daniel F, Pilalis E, Hörberg J, Hou W, Beauchamp MC, Tourneur-Marsille J, Cazals-Hatem D, Sommerova L, Samali A, Tavernier J, Hrstka R, Dupont A, Fessart D, Delom F, Fernandez-Zapico ME, Jansen G, Eriksson LA, Thomas DY, Jerome-Majewska L, Hupp T, Chatziioannou A, Chevet E, Ogier-Denis E.

EMBO Mol Med. 2019 Jun;11(6). pii: e10120. doi: 10.15252/emmm.201810120.

5.

Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.

Quillien V, Carpentier AF, Gey A, Avril T, Tartour E, Sejalon F, Campillo-Gimenez B, Vauleon E.

Cancer Immunol Immunother. 2019 Jun;68(6):871-882. doi: 10.1007/s00262-019-02317-9. Epub 2019 Mar 4.

6.

The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line.

Monnier A, Boniface R, Bouvet R, Etcheverry A, Aubry M, Avril T, Quillien V, Chevet E, Mosser J.

BMC Cancer. 2018 Dec 4;18(1):1213. doi: 10.1186/s12885-018-5094-y.

7.

Transcription of the NKG2D ligand MICA is suppressed by the IRE1/XBP1 pathway of the unfolded protein response through the regulation of E2F1.

Obiedat A, Seidel E, Mahameed M, Berhani O, Tsukerman P, Voutetakis K, Chatziioannou A, McMahon M, Avril T, Chevet E, Mandelboim O, Tirosh B.

FASEB J. 2019 Mar;33(3):3481-3495. doi: 10.1096/fj.201801350RR. Epub 2018 Nov 19.

PMID:
30452881
8.

Alterations of EDEM1 functions enhance ATF6 pro-survival signaling.

Papaioannou A, Higa A, Jégou G, Jouan F, Pineau R, Saas L, Avril T, Pluquet O, Chevet E.

FEBS J. 2018 Nov;285(22):4146-4164. doi: 10.1111/febs.14669. Epub 2018 Oct 20.

9.

Low-Protein Diet Induces IRE1α-Dependent Anticancer Immunosurveillance.

Rubio-Patiño C, Bossowski JP, De Donatis GM, Mondragón L, Villa E, Aira LE, Chiche J, Mhaidly R, Lebeaupin C, Marchetti S, Voutetakis K, Chatziioannou A, Castelli FA, Lamourette P, Chu-Van E, Fenaille F, Avril T, Passeron T, Patterson JB, Verhoeyen E, Bailly-Maitre B, Chevet E, Ricci JE.

Cell Metab. 2018 Apr 3;27(4):828-842.e7. doi: 10.1016/j.cmet.2018.02.009.

10.

Dual IRE1 RNase functions dictate glioblastoma development.

Lhomond S, Avril T, Dejeans N, Voutetakis K, Doultsinos D, McMahon M, Pineau R, Obacz J, Papadodima O, Jouan F, Bourien H, Logotheti M, Jégou G, Pallares-Lupon N, Schmit K, Le Reste PJ, Etcheverry A, Mosser J, Barroso K, Vauléon E, Maurel M, Samali A, Patterson JB, Pluquet O, Hetz C, Quillien V, Chatziioannou A, Chevet E.

EMBO Mol Med. 2018 Mar;10(3). pii: e7929. doi: 10.15252/emmm.201707929.

11.

Regulation of tumor-stroma interactions by the unfolded protein response.

Obacz J, Avril T, Rubio-Patiño C, Bossowski JP, Igbaria A, Ricci JE, Chevet E.

FEBS J. 2019 Jan;286(2):279-296. doi: 10.1111/febs.14359. Epub 2017 Dec 29. Review.

12.

CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.

Avril T, Etcheverry A, Pineau R, Obacz J, Jegou G, Jouan F, Le Reste PJ, Hatami M, Colen RR, Carlson BL, Decker PA, Sarkaria JN, Vauléon E, Chiforeanu DC, Clavreul A, Mosser J, Chevet E, Quillien V.

Clin Cancer Res. 2017 Dec 1;23(23):7360-7374. doi: 10.1158/1078-0432.CCR-17-1549. Epub 2017 Sep 22.

13.

Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers.

Avril T, Vauléon E, Chevet E.

Oncogenesis. 2017 Aug 28;6(8):e373. doi: 10.1038/oncsis.2017.72. Review.

14.

Control of the Unfolded Protein Response in Health and Disease.

Doultsinos D, Avril T, Lhomond S, Dejeans N, Guédat P, Chevet E.

SLAS Discov. 2017 Aug;22(7):787-800. doi: 10.1177/2472555217701685. Epub 2017 Apr 28. Review.

PMID:
28453376
15.

Endoplasmic reticulum proteostasis in glioblastoma-From molecular mechanisms to therapeutic perspectives.

Obacz J, Avril T, Le Reste PJ, Urra H, Quillien V, Hetz C, Chevet E.

Sci Signal. 2017 Mar 14;10(470). pii: eaal2323. doi: 10.1126/scisignal.aal2323. Review.

PMID:
28292956
16.

Reprint of: Signaling the Unfolded Protein Response in primary brain cancers.

Le Reste PJ, Avril T, Quillien V, Morandi X, Chevet E.

Brain Res. 2016 Oct 1;1648(Pt B):542-552. doi: 10.1016/j.brainres.2016.06.021. Epub 2016 Jun 27. Review.

PMID:
27362469
17.

Secretion of protein disulphide isomerase AGR2 confers tumorigenic properties.

Fessart D, Domblides C, Avril T, Eriksson LA, Begueret H, Pineau R, Malrieux C, Dugot-Senant N, Lucchesi C, Chevet E, Delom F.

Elife. 2016 May 30;5. pii: e13887. doi: 10.7554/eLife.13887.

18.

Endoplasmic Reticulum Stress and the Hallmarks of Cancer.

Urra H, Dufey E, Avril T, Chevet E, Hetz C.

Trends Cancer. 2016 May;2(5):252-262. doi: 10.1016/j.trecan.2016.03.007. Epub 2016 Apr 23. Review.

PMID:
28741511
19.

Signaling the Unfolded Protein Response in primary brain cancers.

Le Reste PJ, Avril T, Quillien V, Morandi X, Chevet E.

Brain Res. 2016 Jul 1;1642:59-69. doi: 10.1016/j.brainres.2016.03.015. Epub 2016 Mar 23. Review.

20.

Proteostasis trumps YAP in colon cancer.

Avril T, Chevet E.

Sci Signal. 2015 Oct 6;8(397):fs18. doi: 10.1126/scisignal.aad3123.

PMID:
26443703
21.

Identification of two glioblastoma-associated stromal cell subtypes with different carcinogenic properties in histologically normal surgical margins.

Clavreul A, Etcheverry A, Tétaud C, Rousseau A, Avril T, Henry C, Mosser J, Menei P.

J Neurooncol. 2015 Mar;122(1):1-10. doi: 10.1007/s11060-014-1683-z. Epub 2014 Dec 13.

22.

Proteomic analysis underlines the usefulness of both primary adherent and stem-like cell lines for studying proteins involved in human glioblastoma.

Collet B, Avril T, Aubry M, Hamlat A, Le Reste PJ, Chiforeanu D, Vauleon E, Mosser J, Quillien V.

J Proteomics. 2014 Oct 14;110:7-19. doi: 10.1016/j.jprot.2014.07.022. Epub 2014 Aug 1.

PMID:
25088051
23.

Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.

Clavreul A, Guette C, Faguer R, Tétaud C, Boissard A, Lemaire L, Rousseau A, Avril T, Henry C, Coqueret O, Menei P.

J Pathol. 2014 May;233(1):74-88. doi: 10.1002/path.4332. Epub 2014 Feb 20.

PMID:
24481573
24.

Proteomic analysis of glioblastomas: what is the best brain control sample?

Lemée JM, Com E, Clavreul A, Avril T, Quillien V, de Tayrac M, Pineau C, Menei P.

J Proteomics. 2013 Jun 24;85:165-73. doi: 10.1016/j.jprot.2013.04.031. Epub 2013 May 4.

25.

Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.

Eimer S, Dugay F, Airiau K, Avril T, Quillien V, Belaud-Rotureau MA, Belloc F.

Neuro Oncol. 2012 Dec;14(12):1441-51. doi: 10.1093/neuonc/nos266. Epub 2012 Oct 26.

26.

Isolation of a new cell population in the glioblastoma microenvironment.

Clavreul A, Etcheverry A, Chassevent A, Quillien V, Avril T, Jourdan ML, Michalak S, François P, Carré JL, Mosser J; Grand Ouest Glioma Project Network, Menei P.

J Neurooncol. 2012 Feb;106(3):493-504. doi: 10.1007/s11060-011-0701-7. Epub 2011 Sep 18.

PMID:
21928115
27.

Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.

Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, Diabira S, Mosser J, Quillien V.

Brain Pathol. 2012 Mar;22(2):159-74. doi: 10.1111/j.1750-3639.2011.00515.x. Epub 2011 Sep 16.

PMID:
21790828
28.

Mechanisms of immunomodulation in human glioblastoma.

Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V.

Immunotherapy. 2011 Apr;3(4 Suppl):42-4. doi: 10.2217/imt.11.39. Review.

PMID:
21524170
29.

Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach.

Collet B, Guitton N, Saïkali S, Avril T, Pineau C, Hamlat A, Mosser J, Quillien V.

Proteome Sci. 2011 Apr 6;9(1):16. doi: 10.1186/1477-5956-9-16.

30.

Overview of cellular immunotherapy for patients with glioblastoma.

Vauleon E, Avril T, Collet B, Mosser J, Quillien V.

Clin Dev Immunol. 2010;2010. pii: 689171. doi: 10.1155/2010/689171. Epub 2010 Oct 4. Review.

31.

Safety, pharmacokinetic, and pharmacodynamic evaluations of PI-2301, a potent immunomodulator, in a first-in-human, single-ascending-dose study in healthy volunteers.

Kovalchin J, Krieger J, Collins K, Genova M, Augustyniak M, Masci A, Avril T, Gandon G, Patat A, Fauchoux N, Toutin C, Lacoste E, Patel U, Mascioli E, Zanelli E.

J Clin Pharmacol. 2011 May;51(5):649-60. doi: 10.1177/0091270010373930. Epub 2010 Oct 12.

PMID:
20940336
32.

Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.

Avril T, Saikali S, Vauleon E, Jary A, Hamlat A, De Tayrac M, Mosser J, Quillien V.

J Neuroimmunol. 2010 Aug 25;225(1-2):22-33. doi: 10.1016/j.jneuroim.2010.04.003. Epub 2010 May 20.

33.

Not all polyriboinosinic-polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs.

Avril T, de Tayrac M, Leberre C, Quillien V.

J Immunother. 2009 May;32(4):353-62. doi: 10.1097/CJI.0b013e31819d29bf.

PMID:
19342970
34.

Negative regulation of leucocyte functions by CD33-related siglecs.

Avril T, Attrill H, Zhang J, Raper A, Crocker PR.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1024-7.

PMID:
17073742
35.

Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy.

Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, Guegan Y, Quillien V.

J Neurooncol. 2007 Jan;81(2):139-48. Epub 2006 Sep 27.

PMID:
17004103
38.

Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.

Avril T, Freeman SD, Attrill H, Clarke RG, Crocker PR.

J Biol Chem. 2005 May 20;280(20):19843-51. Epub 2005 Mar 15.

40.

Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms.

Nicoll G, Avril T, Lock K, Furukawa K, Bovin N, Crocker PR.

Eur J Immunol. 2003 Jun;33(6):1642-8.

41.

Human choriocarcinoma cell resistance to natural killer lysis due to defective triggering of natural killer cells.

Avril T, Iochmann S, Brand D, Bardos P, Watier H, Thibault G.

Biol Reprod. 2003 Aug;69(2):627-33. Epub 2003 Apr 30.

PMID:
12724286
42.

Choriocarcinoma cell line resistance to NK lysis mainly involves an HLA-G-independent mechanism.

Avril T, Jarousseau AC, Watier H, Bardos P, Thibault G.

Transplant Proc. 1999 Jun;31(4):1866-7. No abstract available.

PMID:
10371976
43.

Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism.

Avril T, Jarousseau AC, Watier H, Boucraut J, Le Bouteiller P, Bardos P, Thibault G.

J Immunol. 1999 May 15;162(10):5902-9.

Supplemental Content

Support Center